Iron Mountain Inc vs Revvity Inc — how do they compare? Iron Mountain Inc trades at $114.51 (market cap $34.46B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Iron Mountain Inc is far larger — about 2× Revvity Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Revvity Inc for 12 Days on average.
| IRM | RVTY | |
|---|---|---|
Market Cap | $34.46B | $16.98B |
Volume | 1,379,608 | 1,456,900 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $157.36 |
52-Week Low | $78.86 | $82.26 |
Typical Hold Time | 80 Days | 12 Days |
Enterprise Value | $53.87B | $19.30B |
Dividend Yield | 2.99% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $112.97, down 2.38% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed from 10.91% to 2.09% over the same period. Recent news highlights expansion in data center capacity and digital partnerships, while institutional investors show mixed positioning with significant options activity.
The stock presents a growth story with data center expansion driving revenue, but faces headwinds from high debt levels (79.04% debt-to-asset ratio) and margin pressure. Analyst consensus remains bullish with a $142.75 price target representing 26% upside, though technical indicators suggest near-term caution. Key risks include interest rate sensitivity and execution challenges in digital transformation initiatives.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →